To test the antiviral effect against SARS-CoV-2 of a variety of inhibitors to provide a basis for short/medium term treatment for patients with COVID-19.
To evaluate the effectiveness against human coronaviruses of derivatives of the foot and mouth disease virus genome (ncRNAs) and their biological activity in mice and pigs. The antiviral effect exerted by two widely used low-cost generic drugs ready for use in humans (valproic acid and lauryl gallate) will also be explored, along with their potential synergy with Remdesivir, a compound with promising activity against SARS-CoV-2.
Principal Investigators: Margarita Sáiz, Francisco Sobrino (CBMSO)
